1. Comparative Dosing of Adjunctive Corticosteroids Therapy for Pneumocystis Pneumonia with ARDS in Non-HIV Immunocompromised Patients
- Author
-
Li X, Guan L, Wang D, Tang X, Wang R, Li Y, Tong Z, Sun B, and Wang C
- Subjects
adjuvant corticosteroids ,pneumocystis jirovecii pneumonia ,pcp ,acute respiratory distress syndrome ,ards ,non-human immunodeficiency virus ,non-hiv ,Infectious and parasitic diseases ,RC109-216 - Abstract
Xuyan Li,1 Lujia Guan,1 Dong Wang,1 Xiao Tang,1 Rui Wang,1 Ying Li,1 Zhaohui Tong,1 Bing Sun,1 Chen Wang2– 5 1Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, People’s Republic of China; 2Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China; 3National Clinical Research Center for Respiratory Diseases, Beijing, 100029, People’s Republic of China; 4Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China; 5Department of Respiratory Medicine, Capital Medical University, Beijing, 100069, People’s Republic of ChinaCorrespondence: Bing Sun; Chen Wang, Email sunbing20002023@163.com; birm2022@126.comBackground: Adjuvant corticosteroids are effective in patients with human immunodeficiency virus (HIV)-associated Pneumocystis jirovecii pneumonia (PCP) patients, but the effectiveness of adjuvant corticosteroids in non-HIV PCP remained controversial. This study aimed to evaluate the effectiveness of standard-dose compared with low-dose steroids in non-HIV PCP patients with acute respiratory distress syndrome (ARDS).Methods: This retrospective observational study included non-HIV PCP patients with ARDS admitted to the respiratory intensive care unit (RICU) of Beijing Chao-Yang Hospital from 2015 to 2022. Demographics, clinical characteristics, and outcomes were compared between patients receiving standard-dose and those receiving low-dose steroids. Survival times were assessed using Kaplan-Meier curves and compared with the Log rank test. Cox proportional hazards regression analysis was conducted to identify independent risk factors for 28-day and 60-day mortality.Results: A total of 105 non-HIV PCP with ARDS were included, with 48 patients in the standard-dose steroid group (66.7% male, 50.5± 12.6 years) and 57 in the low-dose steroid group (61.4% male, 55.5± 14.2 years). The 60-day mortality was lower in the standard-dose group than in the low-dose group (63.2% vs 48.3%, p=0.04), while 28-day mortality showed no significant difference (50.8% vs 35.4%, p=0.11). After adjusting for confounders, standard-dose steroids reduced 28-day mortality (aHR: 0.339, 95% CI: 0.147– 0.780) and 60-day mortality (aHR: 0.328, 95% CI: 0.152– 0.709), particularly in patients aged < 65 years, non-smokers, those requiring mechanical ventilation, with albumin< 30 g/L, or a PaO2/FiO2 ratio < 150 mmHg. No differences in co-infections or gastrointestinal bleeding were observed.Conclusion: The standard-dose steroid therapy significantly reduced 28-day and 60-day mortality without major complications in the non-HIV immunocompromised population with severe PCP with ARDS. These findings highlight the potential survival benefit of standard-dose corticosteroid regimen in this population.Keywords: adjuvant corticosteroids, Pneumocystis jirovecii pneumonia, acute respiratory distress syndrome, non-human immunodeficiency virus
- Published
- 2024